ABOUT MATRIX BIOMED, INC.
Matrix Biomed, Inc. is a biopharmaceutical company focused on improved drug development through genetic profiling. Gene-based therapeutics target both the dysregulation of one or more genes, as well as gene-gene interactions. Matrix Biomed, Inc. redefines disease models by establishing extensive gene regulatory networks and gene co-expression networks that identify abnormal gene expression in the disease, relative to a healthy state. By redefining human diseases within these networks, Matrix Biomed, Inc. develops therapeutic formulations of compounds shown to restore the abnormally expressed genes to the healthy state. By establishing the genes involved in the disease mechanism Matrix Biomed, Inc. accelerates the discovery and identification of novel therapeutic approaches to efficiently treat the disease without unappreciated negative side effects.
Matrix Biomed, Inc. departs with standard industry practices by extensively exploring the functional connection between drugs, genes, and diseases. By departing with these practices, Matrix Biomed, Inc.’s objective is to increase the relatively low rate at which novel drug candidates are translated into effective clinical therapies. With an average development timeframe of 15 years, a cost of over 1 billion U.S., and a success rate of less than ten percent for discovery of a single novel drug, the pharmaceutical industry is in dire need of reformed models and practices. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state.
Creating A New World For Cancer Treatment
Currently, Matrix Biomed, Inc. gene-based therapeutics has produced drug products for the elimination of the dose-limiting, life-threatening, and treatment-inhibiting toxicities associated with chemotherapy and radiotherapy, making cancer treatment more effective and manageable. Radiation and chemotherapy-induced toxicity remains one of the most significant barriers to the delivery of curative doses of cancer chemotherapy. Particularly troubling are the toxicities specific to individual chemotherapeutic agents that, at minimum, limit the curative dose of cancer chemotherapy and, at a maximum, are lethal to the patient. Some of the most common chemotherapeutic agents belong to one of three classes: anthracyclines (doxorubicin), platinum-based agents (cisplatin), and taxanes (taxol/paclitaxel). Matrix Biomed, Inc.’s current clinical trial designs focus on the prevention of toxicities associated with doxorubicin, cisplatin, and paclitaxel administration.